An unusual combination of latent autoimmune diabetes in young and maturity-onset diabetes in young Authors: Aishwarya Bora, C V S Manasa, Lalitha A V Alekya, Sravanthi Mashetty, Arun Guddeti, K V S Hari Kumar Published: 2026 ABSTRACT AbstractType 1 diabetes mellitus (T1DM) is the most common form of diabetes in young people, and the prevalence of type 2 diabetes mellitus (T2DM) is increasing due to obesity. Latent autoimmune diabetes in adults (LADA) typically presents after age 30, and these patients do not require insulin during the first 6 months after diagnosis. A similar clinical profile presenting before age 30 is known as latent autoimmune diabetes in young (LADY). Maturity-onset diabetes in young (MODY) is a monogenic form of diabetes classified into 14 subtypes based on the pathogenic gene variant and systemic manifestations. We present a 22-year-old woman who was incidentally found to have diabetes at age 18 and had a positive glutamic acid decarboxylase (GAD) antibody. She received oral hypoglycemic agents for the first 4 years and recently started insulin due to poor glycemic control. Whole exome sequencing revealed a heterozygous single-base pair deletion in exon 11 of the carboxyl ester lipase (CEL) gene (chr9:g.133071542del; c.2040del; p.Val681CysfsTer23), suggestive of CEL-MODY, also known as MODY 8. Our report highlights the unusual occurrence of double diabetes (LADY and MODY) in a young woman. Introduction Diabetes mellitus (DM) is a metabolic disorder characterized by either insulin deficiency or resistance and is divided into type 1 (T1DM) and type 2 (T2DM), respectively [1]. Historically, it has been thought that T1DM is the more common presentation of diabetes in the young whereas T2DM is the more common presentation of diabetes in adults, although recent studies suggest a rising incidence of both T1DM in adults and T2DM in the young [2]. Patients with overlapping clinical features are difficult to categorize into either type and are often referred to as double diabetes or type 1.5 diabetes [3]. The American Diabetes Association (ADA) standards of care suggest that people with diabetes be classified into appropriate diagnostic categories and glutamic acid decarboxylase (GAD) should be the primary antibody measured for the diagnosis of autoimmune diabetes [4]. Latent autoimmune diabetes in adults (LADA) is a type of autoimmune diabetes with presentation after 30 years, positive autoantibodies, and not requiring insulin for at least 6 months after diagnosis [5]. A similar profile, if identified before age 30 years, is classified as latent autoimmune diabetes in young (LADY) [6]. Islet function declines rapidly in patients with LADY compared with LADA, and they may have fewer susceptible HLA haplotypes [7]. Maturity-onset of diabetes in young (MODY) is a monogenic form of diabetes with many subtypes characterized by pancreatic β-cell dysfunction and diabetes [8]. MODY is classified into subtypes based on pathogenic variants, and the most common subtypes are due to HNF4A, HNF1B, and HNF1A pathogenic variants [9]. MODY8 is a rare subtype characterized by heterozygous mutation in the carboxyl ester lipase (CEL) gene (OMIM*114840). Patients with CEL MODY have pancreatic exocrine dysfunction, lipomatosis, and pancreatic cysts [10]. We report a young woman with an initial clinical profile of LADY and a high-risk HLA haplotype for autoimmune diabetes. Whole exome sequencing revealed CEL-MODY, also known as MODY8, resulting in an unusual combination of double diabetes. Case presentation A 22-year-old woman was referred for management of diabetes to our department. She was initially detected to have diabetes during an evaluation for a urinary tract infection at the age of 18 years. The young woman is the second child born out of a third-degree consanguineous marriage, and her brother had been diagnosed with protein-losing enteropathy. Both of her parents and maternal uncles were diagnosed with T2DM and are being managed with oral antidiabetic drugs (OAD) and insulin. She was non-obese and had no osmotic features or urine ketones, and her glycosylated hemoglobin (HbA1c) was 8.2% (SI: 66 mmol/mol) (reference range: 4.2-5.6% [SI: 22-38 mmol/mol]) at the time of diagnosis. Her GAD antibody titer was 224.6 IU/mL (reference range: below 10 IU/mL) along with normal hematological and biochemical parameters. Other available markers for insulin secretion done initially are given in Table 1. She, along with her caregivers, refused insulin initially due to the asymptomatic detection of diabetes and was started on metformin 1000 mg daily. Her glycemic control partially improved and required the addition of other OADs, including pioglitazone, sitagliptin, and empagliflozin, over the next 4 years. Her HbA1c range, along with the serial addition of OAD, is shown in Fig. 1. She had a normal menstrual history with no major medical ailments in childhood. She denied features suggestive of microvascular or macrovascular damage, steatorrhea, and hospital admission with uncontrolled hyperglycemia or ketosis during the last 4 years. She became symptomatic with polyuria associated with 1 kg weight loss, along with poor glycemic control and HbA1c of 8.5% (69 mmol/mol) recently, and was referred to us for further management. Serial change in the HbA1c and OAD agents. Table 1Results of the insulin and c-peptide at diagnosis and after 3.5 yearsReference rangeAt diagnosis(Jan 2022)Recent(Aug 2025)Percentage decline over 3.5 yearsFasting insulin3-25 µIU/mL(SI: 18-180 pmol/L)5.1 µIU/mL(30.6 pmol/L)3.02 µIU/mL(18.1 pmol/L)41%Fasting c-peptide0.81-3.85 ng/mL(SI: 264.8-1274.4 pmol/L)2.12 ng/mL(701.7 pmol/L)0.87 ng/mL(288 pmol/L)59%Stimulated c-peptide3-10 ng/mL(SI: 993-3310 pmol/L)2.69 ng/mL(890.4 pmol/L)1.32 ng/mL(436.9 pmol/L)51% Results of the insulin and c-peptide at diagnosis and after 3.5 years Diagnostic assessment On examination, the patient's height was 156 cm and weight 49 kg with a body mass index (BMI) of 20.1 kg/m2. Her supine blood pressure was 122/72 mm Hg, with no postural drop. She had no acanthosis, skin tags, or diabetes complications, and the rest of the systemic examination was normal. Considering the patient's long duration of diabetes with GAD positivity, a comprehensive laboratory screening was ordered to evaluate for diabetes control and related complications. The results showed normal hematological and biochemical parameters and the absence of ketones. We did not check for zinc transporter 8 and islet tyrosine phosphatase 2 antibodies because the patient had a significantly elevated GAD antibody titer at diagnosis. Her celiac screening test using tissue transglutaminase IgA antibody was negative. Chest X-ray was normal and ultrasonography of the abdomen showed a normally sized pancreas and kidneys with no cysts. Her HbA1c was 8.6% (70 mmol/mol), basal c-peptide 0.87 ng/mL (SI: 288 pmol/L) (reference range: 0.81-3.85 ng/mL [SI: 264.8-1274.4 pmol/L]) and stimulated c-peptide was 1.32 ng/mL (436.9 pmol/L) (reference range: 3-10 ng/mL [SI: 993-3310 pmol/L]), suggestive of suboptimal β-cell reserve. Table 1 compares c-peptide at diagnosis and current evaluation, indicating a more than 50% decline in β-cell function over the last 3.5 years. Her thyroid profile showed thyrotropin 6.8 µIU/mL (SI: 6.8 mIU/L) (reference range, 0.4-4.5 µIU/mL [SI: 0.4-4.5 mIU/L]), total thyroxine 8.3 µg/dL (SI: 106.8 nmol/L) (reference range, 4.2-11.5 µg/dL [SI: 54-148 nmol/L]), total triiodothyronine 124 ng/dL (SI: 2.1 nmol/L) (reference range, 75-210 ng/dL [SI: 1.1-3.2 nmol/L]), thyroid peroxidase antibody 1600 IU/L (reference range, <60 IU/L), and fecal elastase was 185 µg/g (reference range: >200 µg/g). In view of the atypical progression of autoimmune diabetes in a young woman, along with a strong family history of diabetes and her brother having a monogenic condition, we performed the HLA typing and whole exome sequencing. Her HLA typing showed the DRB1*03:01:01G DQB1*05:01:01G allele, suggestive of a high risk for autoimmune diabetes. Her whole exome sequencing identified a heterozygous single-base pair deletion in exon 11 of the CEL gene (chr9:g.133071542del; c.2040del; p.Val681CysfsTer23), suggestive of CEL-MODY, also known as MODY 8. The above variant has not been reported previously, and loss-of-function variants in this gene have been reported to cause MODY8. Treatment The patient was treated with a basal-bolus regimen of insulin degludec and aspart. All OADs have been discontinued except for sitagliptin (100 mg) and metformin (1000 mg) daily. Her insulin dose was adjusted based on self-monitoring of glucose. She was prescribed levothyroxine 25 mcg daily and pancreatic enzyme supplements. The patient is under regular follow-up to monitor for the development of systemic complications of diabetes and pancreatic exocrine deficiency. Outcome and follow-up During the last 6 months of follow-up, glycemic control improved, and body weight increased to 56 kg. She had 1 episode of documented hypoglycemia resulting from a mismatch between insulin administration and meal intake. The parents have been repeatedly counseled about genetic screening for other family members. However, they have not agreed due to financial constraints. Her current daily insulin requirement is 12 units of degludec and 16 units of aspart, given in split doses. Her HbA1c was 6.6% (49 mmol/mol) and thyrotropin 2.8 µIU/mL (2.8 mIU/L), both well controlled during the recent hospital visit. Discussion We present a young woman with coexisting LADY and MODY. Our patient had an incidental diagnosis of diabetes during presentation with a simple urinary tract infection. Her GAD antibody positivity at the onset of diabetes confirms the diagnosis of autoimmune diabetes as per the ADA guidelines [4]. However, the patient and family members' reluctance to use insulin led to the prescription of OAD for the next 4 years. Her endogenous insulin production gradually decreased over these 4 years, contributing to poor glycemic control. LADA is also known as slowly progressive T1DM, and its diagnostic criteria were recently revised by the Japanese Diabetes Association [11]. The revised criteria focus on the presence of ketosis, β-cell reserve, and autoimmunity, which help classify the type of diabetes. Patients with LADY usually have a rapid decline in β-cell function, and it is unusual in our case to have an insulin requirement 4 years after the diagnosis. CEL MODY is characterized by pancreatic exocrine and endocrine deficiency with the presence of pancreatic cysts [12]. Our patient had a mild exocrine deficiency, but the pancreatic imaging was normal. Fecal elastase is the only available marker for the assessment of pancreatic exocrine function and the observed value suggests a mild deficiency. Double diabetes is a broad term that denotes the presence of overlapping clinical features between T1DM and T2DM. However, our patient had features of double diabetes due to 2 different monogenic forms of diabetes. The combination of 2 monogenic forms of diabetes has been published rarely in the literature [13-16]. Miller A et al have published a report of MODY5 misdiagnosed as T1DM due to a weak positive GAD antibody titer [13]. Sjoholm A reported the accidental diagnosis of GAD positivity in a 73-year-old male with HNF1A MODY [14]. Donovan et al have published 3 cases of autoimmune diabetes with different types of MODY [15]. It is reported that less than 1% of patients with MODY have autoantibodies, and it is mandatory to enquire about the development of diabetes in family members during every OPD visit. Zhou et al have reported that the pathogenic variant responsible for the MODY may facilitate the progression of LADA [16]. Our patient showed a few atypical features in comparison with previous reports of LADY [17, 18]. Zachariah S et al have described the profile of a young woman similar to that of our patient with a prolonged course of LADY [17]. However, they did not evaluate for MODY due to a lack of a strong family history in that patient. Matsuda et al have described a patient with LADY who had 2 episodes of ketosis and a protective HLA haplotype from the occurrence of T1DM [18]. The HLA profile in our patient was suggestive of increased risk for autoimmune diabetes. T1DM and LADY have strong HLA associations with linkage to DQA and DQB genes [19]. Previous reports suggest that the susceptibility patterns of HLA genotypes are the same between the T1DM and LADY [20]. Most of the previous reports have used sulfonylureas in patients with LADY, and our patient was prescribed non-sulfonylurea drugs. Few authors have shown the long-term beneficial effects of sitagliptin in patients with LADA [21]. We did not consider using sulfonylureas because of the long-standing autoimmune diabetes, and the patient was already using 4 OAD with poor glycemic control. Sulfonylureas are specifically used in the MODY1 and MODY3 subtypes of monogenic diabetes, and a poor response to sulfonylureas is a hidden clue to consider LADA in a patient otherwise treated as T2DM. Praveen et al have established a nationwide registry of youth-onset diabetes in India, and the data showed that 1.7% of patients have a profile similar to LADY [22]. Our patient was 18 years old at the time of diabetes diagnosis and remained insulin-independent for the next 4 years despite being positive for GAD antibody. Her strong family history of diabetes prompted genetic testing, which revealed CEL-MODY. Our case emphasizes the importance of performing a thorough workup in all cases of atypical diabetes. Learning points LADY and MODY types of diabetes may co-exist in the same patient. LADY and MODY types of diabetes may co-exist in the same patient. The insulin-independent period may last up to 4 years in a few patients with LADY. The insulin-independent period may last up to 4 years in a few patients with LADY. Exocrine pancreatic deficiency may not be present in every case of CEL-MODY. Exocrine pancreatic deficiency may not be present in every case of CEL-MODY. In addition to autoantibody testing, HLA typing and whole exome sequencing may help in the diagnosis of diabetes subtypes. In addition to autoantibody testing, HLA typing and whole exome sequencing may help in the diagnosis of diabetes subtypes. Contributors All authors made individual contributions to authorship. A.B., C.V.S.M., L.A.V.A., and K.V.S.H.K. were involved in the diagnosis and management of the patient. S.M. and A.G. were involved in the genetic analysis and preparation of image. All authors reviewed and approved the final draft.